Skip to main content

Understanding Treatment Barriers and Adherence Among People Living with Amyotrophic Lateral Sclerosis in Real World Clinical Practice

Lead Author: Genevieve Matte, MDCM, FRCP (Presenter)

Published: 2024 Canadian Neurological Sciences Federation (CNSF) Congress

Date: May 20 - 26, 2024

Read more (opens new window)

Assessment of AMX0114, An Antisense Oligonucleotide Targeting Calpain-2, in Multiple Models of Axonal Degeneration

Lead Author: Evan Mizerak (Presenter)

Published: TIDES USA | Oligonucleotide & Peptide Therapeutics

Date: May 14 - 17, 2024

Read more (opens new window)

Results From a Global Phase 3 Trial Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis

Lead Author: Leonard H van den Berg, MD, PhD (Presenter)

Published: American Academy of Neurology Annual Meeting 2024

Date: April 13 - 18, 2024

Read more (opens new window)

ORION: A Global, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy

Lead Author: Günter Höglinger, MD (Presenter)

Published: AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)

Date: March 5 - 9, 2024

Read more (opens new window)

Findings From a Pharmacokinetic and Pharmacodynamic Study of Sodium Phenylbutyrate and Taurursodiol in Participants With Amyotrophic Lateral Sclerosis

Lead Author: James Wymer, MD (Presenter)

Published: 2024 MDA Clinical & Scientific Conference (MDA)

Date: March 3 - 6, 2024

Read more (opens new window)

Next Steps in Development for AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Joshua Cohen

Published: 2024 MDA Clinical & Scientific Conference (MDA)

Date: March 3 - 6, 2024

Read more (opens new window)

A Joint Model for Assessing Mortality-Adjusted Progression (MAP) in Amyotrophic Lateral Sclerosis: Application to Clinical Trials of Sodium Phenylbutyrate and Taurursodiol

Lead Author: Ruben van Eijk

Published: International Symposium on ALS/MND (MNDA)

Date: December 6 - 8, 2023

Read more (opens new window)

Effect of Sodium Phenylbutyrate and Taurursodiol on Plasma Concentrations of Neuroinflammatory Biomarkers in Amyotrophic Lateral Sclerosis: Results From the CENTAUR Trial

Lead Author: Robert Bowser, PhD & Jiyan An

Published: Journal of Neurology, Neurosurgery and Psychiatry

Date: December 2, 2023

Read more (opens new window)

Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations

Lead Author: Sara Öhrman (Presenter)

Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Date: November 12 - 15, 2023

Read more (opens new window)

Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease

Lead Author: Lahar Mehta, MD (Presenter)

Published: Clinical Trials on Alzheimer’s Disease (CTAD)

Date: October 24 - 27, 2023

Read more (opens new window)